KR20230014719A - 응고 제viii 인자(f.viii) 기능 대체 활성을 갖는 물질을 중화하는 항체 - Google Patents

응고 제viii 인자(f.viii) 기능 대체 활성을 갖는 물질을 중화하는 항체 Download PDF

Info

Publication number
KR20230014719A
KR20230014719A KR1020227043994A KR20227043994A KR20230014719A KR 20230014719 A KR20230014719 A KR 20230014719A KR 1020227043994 A KR1020227043994 A KR 1020227043994A KR 20227043994 A KR20227043994 A KR 20227043994A KR 20230014719 A KR20230014719 A KR 20230014719A
Authority
KR
South Korea
Prior art keywords
ser
val
thr
gly
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227043994A
Other languages
English (en)
Korean (ko)
Inventor
데쓰히로 소에다
진키 하다노
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20230014719A publication Critical patent/KR20230014719A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4905—Determining clotting time of blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
KR1020227043994A 2020-05-22 2021-05-21 응고 제viii 인자(f.viii) 기능 대체 활성을 갖는 물질을 중화하는 항체 Pending KR20230014719A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-089570 2020-05-22
JP2020089570 2020-05-22
PCT/JP2021/019299 WO2021235537A1 (ja) 2020-05-22 2021-05-21 凝固第viii因子(f.viii)機能代替活性を有する物質を中和する抗体

Publications (1)

Publication Number Publication Date
KR20230014719A true KR20230014719A (ko) 2023-01-30

Family

ID=78708614

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227043994A Pending KR20230014719A (ko) 2020-05-22 2021-05-21 응고 제viii 인자(f.viii) 기능 대체 활성을 갖는 물질을 중화하는 항체

Country Status (6)

Country Link
US (1) US12662552B2 (cg-RX-API-DMAC7.html)
EP (1) EP4155405A4 (cg-RX-API-DMAC7.html)
JP (1) JP7752613B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230014719A (cg-RX-API-DMAC7.html)
CN (1) CN115667515A (cg-RX-API-DMAC7.html)
WO (1) WO2021235537A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026058219A1 (en) * 2024-09-13 2026-03-19 Moonlight Bio, Inc. Engineered cells comprising a dll3 binding receptor or a p53 r175h binding receptor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035756A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二種特異性抗体
WO2006109592A1 (ja) 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha 血液凝固第viii因子の機能代替抗体
WO2012067176A1 (ja) 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
WO2016047656A1 (ja) 2014-09-26 2016-03-31 中外製薬株式会社 凝固第viii因子(fviii)機能代替活性を有する物質を中和する抗体
WO2016047652A1 (ja) 2014-09-26 2016-03-31 公立大学法人奈良県立医科大学 Fviiiの反応性を測定する方法
WO2019065795A1 (ja) 2017-09-29 2019-04-04 中外製薬株式会社 血液凝固第viii因子(fviii)補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035756A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二種特異性抗体
WO2006109592A1 (ja) 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha 血液凝固第viii因子の機能代替抗体
WO2012067176A1 (ja) 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
WO2016047656A1 (ja) 2014-09-26 2016-03-31 中外製薬株式会社 凝固第viii因子(fviii)機能代替活性を有する物質を中和する抗体
WO2016047652A1 (ja) 2014-09-26 2016-03-31 公立大学法人奈良県立医科大学 Fviiiの反応性を測定する方法
WO2019065795A1 (ja) 2017-09-29 2019-04-04 中外製薬株式会社 血液凝固第viii因子(fviii)補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Haemostasis. 1989 19:196-204.
J Thromb Haemost. 2014; 12(2):206-13 Supporting Information
N Engl J Med. 2007;357(6):535-44
Nat Med. 2012; 18(10):1570-74
PLoS One. 2013; 8(2):e57479.
Thromb Diath Haemorrh. 1962 May 15;7:215-28
Thromb Diath Haemorrh. 1975;34(3):869-72
Thromb Haemost. 1995 Feb;73(2):247-51.
Thromb Res. 2011;127 (suppl1):S14-7

Also Published As

Publication number Publication date
WO2021235537A1 (ja) 2021-11-25
CN115667515A (zh) 2023-01-31
US20230183376A1 (en) 2023-06-15
US12662552B2 (en) 2026-06-23
JP7752613B2 (ja) 2025-10-10
EP4155405A1 (en) 2023-03-29
JPWO2021235537A1 (cg-RX-API-DMAC7.html) 2021-11-25
EP4155405A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
JP6702877B2 (ja) 凝固第viii因子(fviii)機能代替活性を有する物質を中和する抗体
KR102436615B1 (ko) Fviii의 반응성을 측정하는 방법
JP7752613B2 (ja) 凝固第viii因子(f.viii)機能代替活性を有する物質を中和する抗体
HK40078605A (en) Antibody for neutralizing substance having coagulation factor viii (f.viii) function substituting activity
HK1232288B (en) Method for measuring reactivity of fviii
NZ729317B2 (en) Method for measuring reactivity of fviii
HK1235415B (en) Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)
HK1235415A1 (en) Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)
BR112017005801B1 (pt) Anticorpo que neutraliza uma substância com atividade de substituir funcionalmente o fator viii da coagulação, e seu método de produção

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000